This study investigated whether the mechanism of action of levetiracetam (LEV) is related to effects on neuronal voltage-gated Na + or T-type Ca 2+ currents. Rat neocortical neurones in culture were subjected to the whole-cell mode of voltage clamping under experimental conditions designed to study voltage-gated Na + current. Additionally, visually identified pyramidal neurones in the CA1 area of rat hippocampal slices were subjected to the whole-cell mode of voltage clamping under experimental conditions designed to study low-voltage-gated (T-type) Ca 2+ current. LEV (10 µM-1 mM) did not modify the Na + current amplitude and did not change (200 µM) the steady-state activation and inactivation, the time to peak, the fast kinetics of the inactivation and the recovery from the steady-state inactivation of the Na + current. Likewise, LEV (32-100 µM) did not modify the amplitude and did not change the steady-state activation and inactivation, the time to peak, the fast kinetics of the inactivation and the recovery from the steady-state inactivation of the T-type Ca 2+ current. In conclusion, neuronal voltage-gated Na + channels do not appear directly involved in the antiepileptic mechanism of action of LEV, and LEV was devoid of effect on the low-voltage-gated (T-type) Ca 2+ current in hippocampal neurones.
INTRODUCTION
Levetiracetam (LEV : (S)-α-ethyl-2-oxo-pyrrolidine acetamide) is a new antiepileptic drug (AED) with a unique pharmacological profile. LEV is devoid of anticonvulsant activity in the two classical screening models for AEDs in mice and rats, the maximal electroshock seizure test and the pentylenetetrazol test 1, 2 . This contrasts potent seizure suppression, a wide safety margin and antiepileptogenic properties in kindling models of epilepsy 2, 3 . Clinical studies have shown that LEV is effective as an add-on therapy in the management of partial-onset seizures in adults 4 . A specific binding site in rat brain has been described for LEV 5 and several studies have demonstrated an ability to antagonize epileptiform responses in rat hippocampal slices in vitro 6, 7 , but the mechanism(s) of action of LEV remain to be characterized.
Inhibitory effects exerted on neuronal excitatory voltage-gated currents, either Na + currents or lowvoltage-activated (T-type) Ca 2+ currents, are cellular mechanisms which are commonly accepted as accounting for the anti-seizure activities (e.g. Reference 8) of several established and newer AEDs. Several reference AEDs-chiefly phenytoin and carbamazepine, but also valproate 9 -as well as the newer AEDs lamotrigine 10 and topiramate 11 have been shown to reduce voltage-gated Na + currents in rat central neurones in culture. The established AEDs ethosuximide, active against absence epilepsy, and dimethadione, have been shown to reduce lowvoltage-activated (T-type) Ca 2+ currents in rodent thalamic neurones in vitro 12 .
The aim of the present study was to establish whether the antiepileptic mechanism(s) of action of LEV involve a modulation of Na + or T-type Ca 2+ channels in mammalian central neurones. Here we report the results of whole-cell patch-clamp record-ings in vitro, investigating possible effects of LEV on voltage-gated Na + currents in rat cortical neurones in culture and on low-voltage-activated (T-type) Ca 2+ currents in the CA3 pyramidal neurones in rat hippocampal slices. Some of these results have been communicated in abstract form 13, 14 .
MATERIALS AND METHODS

Na + currents
Experiments were performed at room temperature on neocortical neurones removed from 14 day old Wistar rat embryos and grown in dissociated cell culture up to 4 weeks in BME (Gibco) with the addition of 10% foetal bovine serum (Gibco), 6 mM glucose, 2 mM glutamine and 100 µg ml −1 of gentamicin (Gibco). The results were obtained from 12 cortical culture preparations.
Membrane currents were recorded from cell somas of fusiform cells, with soma diameters of 20-26 µm, in the whole-cell configuration of the patch-clamp method. The resistance of the patch pipettes was approximately 4 M . The currents were filtered at 3 KHz, digitized by computer at 10 KHz and stored on a hard disc. Leakage currents were subtracted automatically. Test pulses were usually applied at 3 second intervals.
The standard saline bath solution (ACSF) contained (in mM): NaCl, 120; KCl, 3; CaCl 2 , 2; MgCl 2 , 2; glucose 20; HEPES / NaOH, 10; pH 7.3. K + and Ca 2+ currents were blocked by addition of 4-aminopyridine (2 mM) and cadmium (200 µM), respectively. The recording pipettes used for recording sodium currents contained (in mM): CsCl, 130; TEACl, 20; MgCl 2 , 1; CaCl 2 , 0.24; EGTA, 5; ATP, 2; glucose, 10; HEPES/CsOH, 10; pH 7.3. Neurones were perfused with different concentrations of LEV, freshly dissolved in the saline solution and applied by a gravity perfusion system with small (diameter <1 mm) tubes, placed at less than 0.2 cm from the patched cell. During the experiments, the cells were continuously superfused at a flow rate of 0.5-1 ml per minute.
Fitting with Boltzmann sigmoids the plots of the mean normalized Na + current amplitude (I Na /I max Na ) against either the step potential, or the holding potential indicated the potentials V 1/2 , of either halfactivation, or half-inactivation, respectively. The rate of Na + current activation was expressed by the time to peak (TTP), defined as the duration of the rising phase, between the capacitive current and the peak of the Na + current. TTP exponentially decays as a function of the step voltage: TTP ∼ exp(−V /υ act ), with a voltage constant υ act . To characterize the rate of inactivation of the Na + currents-elicited from a holding potential of −80 mV with step voltages increasing from −30 to +30 mV-their fast falling phase was fitted with a single exponential function of time (t): ∼ exp(−t/τ inact ), leading to the time constants τ inact . The exponential decay of τ inact values as a function of the step voltage (V ): τ inact ∼ exp(−V /υ inact ), indicates the voltage constant υ inact . The rate of recovery from inactivation of the Na + currents, having an obvious impact on repetitive neuronal firing, has also been assessed. Na + current was elicited in a two-pulse protocol, by repeated depolarization from a holding potential of −80 to −10 mV, with two 10 ms duration depolarizing steps, separated by inter-pulse intervals ( t) ranging from 0 to 30 ms. Since the Na + current reached a steady-state inactivation over the 10 ms duration of the first depolarizing step, the second step elicited a Na + current whose amplitude increased asymptotically as a function of t: I Na = I max Na [1 − exp(− t/τ rec )], with τ rec representing the time constant of the recovery from inactivation. junction of tetrodotoxin (TTX; 0.75 µM in ACSF), and Cs + (5 mM in ACSF and 110 mM internally) plus TEA (10 mM internally), respectively. High-threshold Ca 2+ currents were cancelled by their fast run-down. Voltage-clamped recordings were collected with sampling rates of either 0.625 or 1 KHz. The T-type currents, isolated as shown in Fig. 3 , did not require any further correction of leak conductance and capacitive transients, but were corrected for the liquid junction potential.
Upon entering into whole-cell configuration, the zero time recording was taken only after complete stabilization of the current, which usually took 20 minutes. After control recordings in normal ACSF, the recordings were performed over 40 minutes perfusion (flow rate 1 ml per minute) of the slices in LEV, either 32 or 100 µM, freshly dissolved in ACSF, or in ACSF alone. These (clinically relevant) concentrations of LEV were used because previous studies have shown that LEV exerts clear-cut in vitro effects in this concentration range, between 10 and 100 µM 6, 7 .
The steady-state activation of the T-type current was studied with voltage steps from −100 to −30 mV. It was characterized by fitting the normalized amplitude of the current with a rising Bolzmann sigmoid:
gives the half-activation potentials (V 1/2 ) and the activation slopes (k). The steady-state inactivation was studied with 1 s conditioning steps increasing from −100 to −30 mV, followed by a step to −30 mV. It was similarly analysed with a falling Bolzmann sigmoid:
which gives the half-inactivation potentials (V 1/2 ) and the slopes (k).
The rising (activation) and the falling (inactivation) phases of the T-type current have been characterized by the same parameters, as defined above for the Na + current: the 'time to peak' (TTP) and the time constant τ inact . Also, the recovery from inactivation has been described by the time constant τ rec , as defined for the Na + current.
Statistics
The quantitative results are expressed as mean ± SEM, for the number of neurones recorded in each group. The statistical significance of differences between experimental groups was assessed with Student's t-test.
RESULTS
Na + currents
When cortical neurones were voltage clamped at −80 mV, a depolarization step to −10 mV elicited an inward current that was completely blocked by 1 µM TTX in the external solution (Fig. 1) . Extracellular perfusion of different concentrations of LEV, from 10 µM to 1 mM, for time intervals from 3 seconds to 10 minutes, did not modify the amplitude of this TTX-sensitive Na + current (I Na ) in 25 neurones, 7-15 days old in culture. In view of the lack of effect of LEV on Na + current amplitude, a high concentration of 200 µM LEV was consistently used in further investigations of the biophysical characteristics of the Na + current, in order to avoid overlooking an effect of the drug which might only appear at the high limit of clinically relevant concentrations. Indeed, a metaanalysis on pharmacokinetic data from the four phase-III studies performed so far with adjunctive therapy of LEV in adults with refractory partial epilepsy reveals that clinically effective doses (1-3 g per day) result in trough plasma levels between 35 and 100 µM and C 1hour (close to C max ) levels between 90 and 250 µM (unpublished results of UCB Pharma 15 ).
In both control ACSF and that containing 200 µM LEV, Na + currents started to activate at a membrane potential of −40 mV and peaked at −10 mV (Fig. 2) . Moreover, LEV did not change the steady-state activation of the Na + currents, elicited from a holding potential of −80 mV. The fit of the mean normalized Na + current amplitude against the step potential, indicated similar half-activation potentials (V 1/2 ) in both control conditions and in the presence of LEV (Table 1). In addition, LEV did not modify the steadystate inactivation of the Na + currents, elicited with voltage steps applied every 5 seconds, from different holding potentials to −10 mV. In both control ACSF and that containing LEV, Na + currents were similarly reduced when the holding potential was more positive than −90 mV and hardly any current could be elicited from holding potentials more positive than −40 mV. The fit of the normalized Na + current amplitude against the holding potential indicated quite similar half-inactivation potentials (V 1/2 ), in control conditions and in the presence of LEV (Table 1) .
Neither TTP values, nor their voltage constant υ act , have been influenced by the perfusion of LEV (Table 2). Likewise, LEV did not influence either the τ inact values, or their voltage constant υ inact , (Table 2) . Also, the recovery from inactivation of the Na + currents, a phenomenon having an obvious impact on the repetitive neuronal firing, was not influenced by LEV, as shown by the time constant of the recovery from inactivation (τ rec ), which was almost identical, irrespective of the presence of LEV (Table 2) .
Low-threshold Ca 2+ currents
From a holding potential of −50 mV, voltage steps between −100 and −10 mV activate the low-threshold (T-type) Ca 2+ current in CA1 pyramidal neurones, together with the leak current and, possibly, a residual high-threshold voltage-activated Ca 2+ current, when the steps are preceded by a 2 seconds pre-step to −120 mV. However, when the steps are preceded by a 2 seconds pre-step to −60 mV, only the leak current and the residual high-threshold Ca 2+ current are activated. Accordingly, the T-type Ca 2+ current is isolated by subtraction of the two families of traces (Fig. 3 ). This T-type Ca 2+ current was blocked by Ni 2+ (200 µM; see the inset in Fig. 3 ) and by Co 2+ (2.5 mM). However, LEV (32 µM, 100 µM) was without effect on the amplitude of the T-type current (Fig. 4) . The data in Table 3 show that neither the steadystate activation, nor the steady-state inactivation of the T-type current, characterized by the potentials of halfeffects (V 1/2 ) and the slopes (k), were influenced by LEV. Likewise, none of the kinetic parameters of the T-type current in CA1 pyramidal neurones, the TTP and the time constants τ inact and τ rec , were influenced by LEV (Table 4) .
DISCUSSION
This study revealed a complete lack of effect of LEV on the neuronal (TTX-sensitive) Na + current, studied with the same methodology with which some of us have previously shown clear-cut inhibitory effects of both established 9 and newer 10, 11 AEDs, and of riluzole 16 . This appears to corroborate pharmacological observations with LEV in animal models of seizures and epilepsy. LEV is distinct from Na + channel blockers like phenytoin and carbamazepine by an absence of anticonvulsant activity in the maximal electroshock seizure test in mice and rats 1, 2 . In contrast, it has been reported that LEV protects against seizures induced by 6 Hz electrical stimulation of mice via corneal electrodes, which is a phenytoin-resistant seizure model 17 .
Furthermore, phenytoin, carbamazepine 18 and, recently, lamotrigine 2 are known to be inactive against focal seizures induced by systemic administration of pilocarpine, while LEV affords potent protection in this model 2 . Together with these results, the findings of the present study suggest that the antiepileptic action of LEV is unlikely to be mediated via inhibition of neuronal Na + channels.
In view of the commonly accepted association between absence epilepsy and the T-type Ca 2+ current (in thalamic neurones), one might have anticipated that LEV, which is active in several rat models of absence epilepsy, would reduce the T-type current in hippocampal neurones, too. Specifically, LEV suppresses spontaneous spike-and-wave discharges in both GAERS rats 19 , and in rats administered a subconvulsant dose of PTZ 20 . Also, the displacement of LEV from its stereo-specific binding site in rat brain membranes by the anti-absence drug ethosuximide at concentrations close to anti-convulsant plasma levels, reported twice 5, 21 , and by the T-type current antagonist amiloride 21 would further favour a possible interaction of LEV with the neuronal T-type current. In addition, the antagonism by LEV of a non-GABA A receptorassociated epileptiform effect of bicuculline in rat hippocampus was mimicked by the non-specific calcium antagonist flunarizine, known to preferentially block the T-type current, while the prototypic L-type calcium channel blocker nifedipine was without effect 22 . Table 4 : Kinetic parameters of T-type current in pyramidal CA1 neurones of rat hippocampal slices, recorded over 40 minutes perfusion in either control ACSF, or levetiracetam (LEV) 32 µM or LEV 100 µM. TTP is the 'time to peak', defined in the text; τ inact is the time constant of the exponential decay of T-type currents; τ rec is the time constant of the recovery from inactivation, arising from the exponential fit of the inter-pulse dependence of T-type current amplitude (see Materials and methods section). The values are given as mean ± SEM, for the number of neurones indicated between parentheses. No difference between the groups is significant. 
In spite of all these indirect suggestions, the results of the present study ( Fig. 4 and Tables 3 and 4) dismiss any direct effect of LEV on the T-type current in rat hippocampal neurones. Obviously, these results cannot exclude, however, a putative effect of LEV on the T-type current in thalamic neurones, on which the activity of the ethosuximide was originally shown 12 . However, our results support the view that an antiabsence activity in vivo is not compulsorily associated with an inhibition of the T-type Ca 2+ current in all rat brain neurones, since LEV, a drug active in rodent models of absence-type seizures, did not affect the T-type current in rat hippocampal neurones. In fact, the anti-absence effects are in no way exclusive to Ttype Ca 2+ channel blockers and the very hypothesis that the therapeutic anti-absence action of ethosuximide arises from a reduction of the T-type current was questioned 23 .
The current understanding of the antiepileptic mechanisms of LEV (whose antiepileptic properties have been revealed by serendipitous screening) is only incipient. The displacement of LEV from its specific binding site in rat brain by the GABA-related convulsants pentylenetetrazole and bemegride 5 suggested possible interactions between the LEV-binding site and the GABA A complex. Subsequently, LEV was reported to increase the activity of the GABA-degrading enzyme GABA aminotransferase (GABA-T) in several regions of the rat brain, including the striatum, where it also decreased the activity of the GABAsynthesizing enzyme glutamic acid decarboxylase (GAD) 24 . A reduced GABAergic activity in the striatum is known to be anticonvulsant 25 , since a disinhibited striatal output enhances the inhibition in the substantia nigra pars reticulata, a brain region which receives a strong GABAergic input from the striatum and controls seizure propagation 26 . Since Löscher et al. 24 recorded, indeed, a decreased spontaneous firing of (presumably) GABAergic neurons in the substantia nigra pars reticulata following LEV, these authors hypothesized that it might contribute to the anticonvulsant action of the drug. However, a wealth of data, starting with the absence of any affinity of LEV for the GABA receptors 5 , prevent ascribing to LEV any conventional GABAergic facilitation. Indeed, the fact that LEV induced (only at the relatively high dose 170 mg kg −1 i.p.) in regions of rat brain both increases and decreases in GABA-T and GAD activities, while not altering the activities of these enzymes in vitro, led Löscher et al. 24 to conclude that the enzyme alterations they found were but indirect consequences of post-synaptic changes. Moreover, GABA turnover was normalized 60 minutes after LEV, casting serious doubts on the anticonvulsant relevance for the antiepileptic action of LEV of the alterations in GABA turnover, since the time of the peak effect of LEV was previously reported to be 60 minutes in both mice and rats 1 . Furthermore, LEV (up to 300 mg kg −1 i.p.; single/multiple doses) had no effect on the concentrations of GABA, glutamate and glutamine, and on the activities of GAD and GABA-T in mice brains 27 . Also, LEV had no effect on GABA transport and metabolism in rat astrocyte culture 28 . Accordingly, it was concluded that it is unlikely that the action of LEV would be mediated via the GABAergic system 27, 28 . Fig. 3 . The graphs represent (mean ± SEM) the current-voltage dependencies before and after 40 minutes perfusion of either ACSF (upper graph, for n = 6 neurones), or LEV 32 µM (middle graph, for n = 10 neurones), or LEV 100 µM (lower graph, for n = 8 neurones). No statistically significant difference was found between the three groups of neurones.
While these studies, along with our results presented above, disclaim for LEV any conventional mechanism currently accepted for the established AEDs, very recent data suggest that LEV might control pathologic neuronal excitability via multiple modulatory actions. To date, these include an inhibition of high-voltageactivated Ca 2+ currents in pyramidal neurons from rat hippocampal slices 29 and a suppression of the inhibitory effects of several negative allosteric modulators, including the Zn 2+ ions and β-carbolines, on both GABA-gated currents in cultured rat hippocampal and cerebellar granule neurons and glycine-gated currents in spinal neurons 30 . Furthermore, an inhibition of the AMPA-gated current in cultured rat hippocampal neurons has also been reported, but only at relatively high concentrations 31 . Obviously, it is too early to conclude on the anti-seizure relevance of these effects and there is little doubt that further cellular effects of LEV might be unraveled in the forthcoming years.
CONCLUSION
This study reveals the absence of effect of LEV on neuronal voltage-activated Na + current and lowvoltage-activated Ca 2+ current, i.e. on two major mechanisms accepted for established AEDs. Along with previous reports, this suggests that LEV exerts its antiepileptic action via non-conventional mechanisms, the exact nature of which can only be identified by future studies. Beyond its mechanistic interest, the outcome of this study is of potential relevance for orienting antiepileptic polytherapy.
